Inmed pharmaceuticals reports third quarter fiscal 2023 financial results and provides business update

Completed enrollment in phase 2 clinical trial; data readout expected during calendar 3q 2023 120% quarter-over-quarter revenue growth in the commercial baymedica subsidiary published a peer-reviewed study showing the anti-inflammatory potential of rare cannabinoids vancouver, british columbia--(newsfile corp. - may 15, 2023) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced financial results for the third quarter of the fiscal year 2023 ("fy 3q23") which ended march 31, 2023.  the company's full financial statements and related md&a for the third quarter ended march 31, 2023, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.
INM Ratings Summary
INM Quant Ranking